Breaking News Instant updates and real-time market news.

PACB

Pacific Biosciences

$5.25

0.07 (1.35%)

07:04
09/28/17
09/28
07:04
09/28/17
07:04

Pacific Biosciences downgraded to Neutral from Buy at CL King

CL King analyst David Westenberg downgraded Pacific Biosciences to Neutral due to fair valuation and raised his fair value estimate to $6.80 from $5.60.

PACB Pacific Biosciences
$5.25

0.07 (1.35%)

12/15/16
CANT
12/15/16
NO CHANGE
Target $15
CANT
Overweight
Cantor says Roche deal termination significant negative for Pacific Biosciences
Cantor Fitzgerald analyst Bryan Brokmeier said Roche's (RHHBY) termination of its collaboration agreement with Pacific Biosciences is a "significant negative" for the latter, as he was forecasting Roche-generated revenues of $14.3M in 2017 and $27.5M in 2018. Pacific Bio should not lose all of that revenue, since it will now be able to sell into the clinical market or partner with another company, but that will require further investments, said Brokmeier, who has an Overweight rating and $15 price target on the stock.
12/15/16
PIPR
12/15/16
NO CHANGE
Target $6
PIPR
Neutral
Pacific Biosciences price target lowered to $6 from $10 at Piper Jaffray
Piper Jaffray analyst William Quirk lowered his price target for Pacific Biosciences (PACB) to $6 from $10 after Roche (RHHBY) terminated its Sequel system contract with the company. Pacific Biosciences believes Roche's decision stems from a change in the sequencing market dynamics, the analyst notes, adding that Roche said "somewhat vaguely" that Sequel can no longer meet a list of requirements the company established. Additionally, Quirk believes the mid-point of Pacific Biosciences' 2017 guidance may be difficult to reach, and reiterates a Neutral rating on the shares.
12/15/16
CANT
12/15/16
NO CHANGE
Target $8
CANT
Overweight
Pacific Biosciences a 'viable takeout target,' says Cantor
Cantor analyst Bryan Brokmeier says Pacific Biosciences' (PACB) shares are oversold after the company announced that Roche (RHHBY) has terminated their IVD-distribution agreement, whereby Roche had exclusive distribution rights of the Sequel into the clinical market. While the analyst acknowledges Roche's termination of the agreement is a clear long-term strategic negative, he says it is not nearly as much as the stock selloff is implying and notes that Pacific Biosciences is now positioned to sell into the clinical sequencing market directly or through other partners. Moreover, Brokmeier believes Pacific Biosciences is now "effectively a viable takeout target" for other companies, with Agilent (A), Bio-Techne (TECH), Illumina (ILMN), PerkinElmer (PKI), Thermo Fisher (TMO), and Roche among potential acquirers. He reiterated an Overweight rating on Pacific Biosciences' stock, but lowered his price target on the shares to $8 from $15.
07/20/17
PIPR
07/20/17
NO CHANGE
Target $4.8
PIPR
Neutral
Pacific Biosciences checks imply potential Q2 downside, says Piper Jaffray
Piper Jaffray analyst William Quirk says his channel checks found 13 Sequel systems in the quarter, down sequentially from 21 found in Q1 and 13 in Q4. Pacific Biosciences typically places two times the channel check, which would imply 26 systems in the quarter, Quirk tells investors in a research note. He lowered his 33 estimate to 30 and sees risk to Q2 numbers. The analyst keeps a Neutral rating on Pacific Biosciences and dropped his price target for the shares to $4.80 from $5.10.

TODAY'S FREE FLY STORIES

HD

Home Depot

$183.67

0.6102 (0.33%)

09:53
02/22/18
02/22
09:53
02/22/18
09:53
Recommendations
Home Depot analyst commentary  »

Home Depot price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

DIS

Disney

$105.78

0.725 (0.69%)

, APO

Apollo Global

$34.00

0.16 (0.47%)

09:52
02/22/18
02/22
09:52
02/22/18
09:52
Periodicals
Judge says Disney misused 'Star Wars' copyrights, Hollywood Reporter reports »

A California federal…

DIS

Disney

$105.78

0.725 (0.69%)

APO

Apollo Global

$34.00

0.16 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 01

    Mar

  • 06

    Mar

  • 07

    Mar

LEXEB

Liberty Expedia Holdings

09:50
02/22/18
02/22
09:50
02/22/18
09:50
Hot Stocks
Breaking Hot Stocks news story on Liberty Expedia Holdings  »

Liberty Expedia Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$16.22

0.12 (0.75%)

09:47
02/22/18
02/22
09:47
02/22/18
09:47
Hot Stocks
Wendy's says testing expanded value menu »

Says raised menu prices…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 07

    Mar

  • 30

    May

TMUS

T-Mobile

$59.42

-1.09 (-1.80%)

, DTEGY

Deutsche Telekom

$16.20

-0.07 (-0.43%)

09:47
02/22/18
02/22
09:47
02/22/18
09:47
Hot Stocks
Deutsche Telekom buys 230K shares of T-Mobile common stock »

In a regulatory filing,…

TMUS

T-Mobile

$59.42

-1.09 (-1.80%)

DTEGY

Deutsche Telekom

$16.20

-0.07 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 05

    Mar

LEXEB

Liberty Expedia Holdings

09:45
02/22/18
02/22
09:45
02/22/18
09:45
Hot Stocks
Breaking Hot Stocks news story on Liberty Expedia Holdings  »

Liberty Expedia Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OC

Owens Corning

09:45
02/22/18
02/22
09:45
02/22/18
09:45
Recommendations
Owens Corning analyst commentary  »

Owens Corning price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:45
02/22/18
02/22
09:45
02/22/18
09:45
General news
U.S. leading indicators preview: »

U.S. leading indicators…

09:45
02/22/18
02/22
09:45
02/22/18
09:45
General news
Breaking General news story  »

New York Federal Reserve…

09:45
02/22/18
02/22
09:45
02/22/18
09:45
General news
Leading Indicators to be reported at 10:00 »

January Leading…

SNAP

Snap

09:43
02/22/18
02/22
09:43
02/22/18
09:43
Hot Stocks
Snap slips after Kylie Jenner critique »

Early weakness in shares…Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 07

    Mar

STMP

Stamps.com

$184.95

-5.1 (-2.68%)

09:43
02/22/18
02/22
09:43
02/22/18
09:43
Recommendations
Stamps.com analyst commentary  »

Stamps.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 23

    May

PG

Procter & Gamble

09:42
02/22/18
02/22
09:42
02/22/18
09:42
Hot Stocks
Procter & Gamble: 'Progress will not come in a straight line' »

Says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 07

    Mar

HST

Host Hotels

, AOBC

American Outdoor Brands

$10.06

-0.12 (-1.18%)

09:40
02/22/18
02/22
09:40
02/22/18
09:40
Options
Unusually active option classes on open February 22nd »

Unusual total active…

HST

Host Hotels

AOBC

American Outdoor Brands

$10.06

-0.12 (-1.18%)

NXPI

NXP Semiconductors

$125.60

0.04 (0.03%)

TMUS

T-Mobile

$59.42

-1.09 (-1.80%)

CHK

Chesapeake

P

Pandora

WMT

Walmart

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 01

    Mar

  • 05

    Mar

  • 07

    Mar

  • 18

    Mar

  • 22

    Mar

  • 23

    Mar

  • 27

    Mar

  • 28

    Mar

LMFA

LM Funding

$1.51

0.08 (5.59%)

, LFIN

Longfin

$34.20

-2.03 (-5.60%)

09:38
02/22/18
02/22
09:38
02/22/18
09:38
Periodicals
LM Funding takeover rumors discussed in web report »

The "GrooveVC"…

LMFA

LM Funding

$1.51

0.08 (5.59%)

LFIN

Longfin

$34.20

-2.03 (-5.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTS

QTS Realty Trust

09:37
02/22/18
02/22
09:37
02/22/18
09:37
Recommendations
QTS Realty Trust analyst commentary  »

QTS Realty Trust price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 04

    Mar

  • 05

    Mar

  • 15

    Mar

  • 03

    Apr

FSLR

First Solar

09:36
02/22/18
02/22
09:36
02/22/18
09:36
Downgrade
First Solar rating change  »

First Solar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 15

    Mar

AVGO

Broadcom

$248.62

-1 (-0.40%)

, QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

09:36
02/22/18
02/22
09:36
02/22/18
09:36
Recommendations
Broadcom, Qualcomm, Xilinx, Analog Devices, Maxim Integrated, Marvell, Microsemi analyst commentary  »

RBC finds takeover…

AVGO

Broadcom

$248.62

-1 (-0.40%)

QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

XLNX

Xilinx

$68.46

-0.73 (-1.06%)

ADI

Analog Devices

MXIM

Maxim Integrated

$61.75

-0.37 (-0.60%)

MRVL

Marvell

$23.19

-0.01 (-0.04%)

MSCC

Microsemi

$60.94

-0.52 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 06

    Mar

  • 08

    Mar

  • 22

    Mar

IDGX

AltheaDx

09:35
02/22/18
02/22
09:35
02/22/18
09:35
Initiation
AltheaDx initiated  »

AltheaDx initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFM

Sprouts Farmers Market

$26.12

0.12 (0.46%)

09:34
02/22/18
02/22
09:34
02/22/18
09:34
Earnings
Sprouts Farmers Market sees FY18 EPS $1.22-$1.28, consensus $1.23 »

Sees FY18 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SFM

Sprouts Farmers Market

$26.12

0.12 (0.46%)

09:33
02/22/18
02/22
09:33
02/22/18
09:33
Earnings
Sprouts Farmers Market reports Q4 EPS 29c, consensus 15c »

Reports Q4 revenue $1.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

NNBR

NN, Inc.

$25.40

0.25 (0.99%)

09:32
02/22/18
02/22
09:32
02/22/18
09:32
Hot Stocks
NN, Inc. acquires Bridgemedica, terms not disclosed »

NN announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

SHPG

Shire

$125.03

-1.64 (-1.29%)

09:31
02/22/18
02/22
09:31
02/22/18
09:31
Recommendations
Shire analyst commentary  »

Shire post results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 23

    Mar

  • 25

    Mar

09:30
02/22/18
02/22
09:30
02/22/18
09:30
General news
U.S. equities are mildly firmer »

U.S. equities are mildly…

AYX

Alteryx

09:30
02/22/18
02/22
09:30
02/22/18
09:30
Recommendations
Alteryx analyst commentary  »

Alteryx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.